NCT02683525View on ClinicalTrials.gov

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 3, 2016

Primary Completion Date

February 13, 2019

Study Completion Date

October 1, 2019

Conditions
Graft vs Host DiseaseHematopoietic Stem Cell Transplantation
Interventions
DRUG

Sitagliptin

600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant

Trial Locations (2)

46202

Indiana University Health Hospital, Indianapolis

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis

All Listed Sponsors
lead

Sherif S. Farag

OTHER

NCT02683525 - Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter